Are there any updates on the company's product pipeline or regulatory milestones?

Answer

Based on the information contained in the news release you provided, there are no specific updates about VolitionRx Limited’s (NYSE AMERICAN: VNRX) product pipeline or any regulatory milestones.

The announcement is solely a notification of an upcoming earnings conference call:

• Date of call: Friday, August 15, 2025
  
• Time: 8:30 a.m. U.S. Eastern Time
  
• Location: Teleconference (details to be provided by the company)

The press release does not include any mention of:

• New pre‑clinical or clinical programs that have been initiated or advanced.
  
• Progress on existing drug candidates (e.g., IND filings, Phase 1/2/3 trial initiations, or trial completions).
  
• Interactions with regulatory agencies (e.g., FDA, EMA, or other health‑authority meetings, submissions, or approvals).
  
• Anticipated regulatory timelines or milestones for any of VolitionRx’s products.

What this means for you

• If you are looking for pipeline or regulatory updates: The current release does not provide them. You will need to wait for the actual conference call on August 15, 2025, where the company typically discusses recent scientific, clinical, and regulatory developments.
  
• Where to find future updates:
  
  • Company’s Investor Relations website – press releases, SEC filings (e.g., 8‑K, 10‑Q), and slide decks posted after the call.
    
  • Regulatory databases (e.g., FDA’s ClinicalTrials.gov, EMA’s EMA‑ClinicalTrials) for any new trial registrations or submissions.
    
  • Subsequent news wires (PR Newswire, Business Wire) that often publish “Business Update” or “Regulatory Milestone” releases shortly after earnings calls.

Bottom line: The current news item is limited to the scheduling of an earnings call and does not contain any product‑pipeline or regulatory‑milestone information. For the latest details, you’ll need to attend the August 15 conference call or monitor the company’s post‑call disclosures.